依达拉奉联合奥扎格雷钠对急性脑梗死神经系统功能恢复的作用探讨

Effect of edaravone combined with ozagrel sodium on recovery of nervous system function in patients with acute cerebral infarction

目的观察依达拉奉与奥扎格雷钠联合治疗进展性脑梗死的临床疗效。方法选择急性脑梗死患者60例,随机分为治疗组和对照组,每组30例。2组均采用常规临床治疗,在此基础上对照组给予奥扎格雷钠80mg,加入生理盐水(NS)250mL,静脉滴注,1次/d;治疗组在对照组治疗基础上给予依达拉奉10mg,加入生理盐水100mL静脉滴注,2次/d。疗程均为14d。对2组患者治疗前后的神经功能缺损程度进行评分,并评价临床疗效。结果 2组患者治疗前美国国立卫生院卒中量表(NIHSS)评分、神经功能缺损评分(NDS)、日常生活活动能力(ADI)评分比较,差异无统计学意义(P>0.05)。2组患者治疗后NIHSS、NDS及ADL评分均优于治疗前,差异有统计学意义(P<0.01);治疗组治疗后NIHSS、NDS及ADL评分均优于对照组治疗后,差异有统计学意义(P<0.01)。对照组治疗总有效率为53.33%;治疗组治疗总有效率90.00%。治疗组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。结论依达拉奉联合奥扎格雷钠治疗急性脑梗死,可明显改善患者神经功能缺损。

Objective To explore the clinical effect of edaravone combined with ozagrel sodiumon on the treatment of patients with acute cerebral infarction（ACI）. Methods 60 patients with ACI were randomly divided into treatment group and control group, 30 cases in each group.Both groups were treated with conventional therapy, and the control group was treated with additional ozagrel 80 mg in 250 mL normal saline（NS）by intravenous infusion, once per day. On the basis of the control group, the treatment group was treated with additional edaravone 10 mg in 100mL NS by intravenous infusion, twice per day. 14 days were counted as a course of treatment. Degree of neurological impairment and clinical efficacy were evaluated in both groups. Results There were no significant differencesof pretherapeutic National Institutesof Health Stroke Scale（NIHSS）score, nervous functional score（NDS）and activity of daily living（ADI）score between the two groups（P 0.05）. After treatment, the NIHSS, NDS and ADI were significantly improved in both groups（P 0.01）, and the post- therapeutic levels of indexes mentioned above in the treatment group were significantly better than those in the control group（P 0.01）. The total effective rate in the treatment group was 90.00%, which was significantly higher than 53.33% in the control group（P 0.05）. Conclusion Application of edaravone combined with ozagrel sodium in the treatment of patients with ACI can significantly improve the status of neurological impairment.